Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DiaTech Oncology Receives New York State Clinical Laboratory Permit

Published: Wednesday, June 26, 2013
Last Updated: Wednesday, June 26, 2013
Bookmark and Share
Predictive test now available to patients and physicians in all 50 states.

DiaTech Oncology announced that the company has received a Clinical Laboratory Permit from the New York State Department of Health (NYS DOH). DiaTech’s predictive assay test — which guides the treating oncologist to the most effective chemotherapy for inducing cell death in the malignant cells of a particular cancer patient — is now available to patients and physicians in all 50 states.

In clinical trials and published research, use of DiaTech Oncology’s test — the MiCK® assay or Correct Chemo® — has consistently shown an increase in complete or partial response rates, longer time to relapse and a trend to longer survival times for more than 50 types of cancers, including lung, breast, colorectal, stomach, prostate, liver, ovarian, esophageal, bladder, non-Hodgkin lymphoma, leukemia and other cancers.

“New York State has the most stringent requirements for laboratory test approval in the United States,” says Garry Latimer, DiaTech CEO. “Receiving this permit is great news for cancer patients. It affirms that our CAP-accredited, CLIA-certified laboratory meets the highest standards for accurate and reliable clinical laboratory services.”

“DiaTech’s predictive assay — the only test on the market that guides the treating oncologist to the most effective chemotherapy for inducing apoptotic cell death in the malignant cells of a particular cancer patient — is now available to more cancer patients and oncologists than ever before,” states Dr. Cary Presant, DiaTech Chief Medical Officer. “Our clinical studies consistently reveal that patients treated with MiCK assay-guided chemotherapy demonstrate longer survival times and lower costs, and our studies are continuing to produce unexpected new leads for innovative therapeutic strategies.”

DiaTech’s patented MiCK assay measures apoptosis, or cell death, in the cancer cells of chemotherapy patients. Tumor cells are exposed to multiple doses of several chemotherapeutic drugs, either as single drugs or combinations. An algorithm monitors and computes the amount of cell death and determines a drug sensitivity “score” of the patients’ tumor cells.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!